There are currently 101 active clinical trials seeking participants for Asthma research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and Ontario.
Project 2 Airway Potential Hydrogen (pH) in Asthma
NCT03617718
Recruiting
This study is testing a non invasive way to measure airway pH in individuals with Asthma and Cystic Fibrosis using a new inhaled drug. The airway pH will help health care providers in creating tailored treatment plans for individuals suffering from these specific conditions.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
03/13/2024
Locations: Indiana University School of Medicine, Indianapolis, Indiana +1 locations
Conditions: Cystic Fibrosis, Asthma, Severe Persistent Asthma, Healthy
Register for Updates
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589
Recruiting
To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled corticosteroids (ICS) and at least one additional asthma controller medication with or without oral corticosteroids.
Gender:
All
Ages:
Between 5 years and 11 years
Trial Updated:
03/13/2024
Locations: Research Site, Montgomery, Alabama +92 locations
Conditions: Asthma
Register for Updates
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
NCT01143480
Recruiting
Background: - Innate immunity is the process by which white blood cells and other parts of the immune system sense and respond to potential infections by causing an inflammation. Researchers are interested in studying how the body responds to certain environmental factors, and whether the body s response can contribute to chronic illnesses or diseases such as asthma and certain types of cancers. Objectives: - To examine how specific genes and proteins in blood cells respond to environmental e... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
03/12/2024
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Asthma, Atherosclerosis, Metabolic Syndrome, Insulin Resistance, Cancer
Register for Updates
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
NCT05097287
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma. The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Cullman Research Center, LLC Site Number : 8400001, Cullman, Alabama +213 locations
Conditions: Asthma
Register for Updates
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315
Recruiting
This is a parallel, Phase 3, 2-arm study to evaluate the efficacy and long-term safety of dupilumab treatment in children 2 to <6 years of age with uncontrolled asthma and/or recurrent severe asthmatic wheeze. The study will be conducted in 2 parts. Part A will be a 52-week, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of dupilumab in children aged 2 to <6 years old with uncontrolled asthma and/or recurrent severe asthmatic wheeze. At the end of Part A, al... Read More
Gender:
All
Ages:
Between 2 years and 5 years
Trial Updated:
03/08/2024
Locations: Allergy & Asthma Specialists, PSC Site Number : 8400002, Owensboro, Kentucky +5 locations
Conditions: Wheezing, Asthma
Register for Updates
Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma
NCT03762395
Recruiting
The main purpose of this Phase 2 double blind, placebo controlled crossover clinical study is to demonstrate the efficacy and safety of CXA-10 in obese adult asthmatics. Obesity induces a chronic systemic inflammatory state characterized by impaired adipokine signaling, pro-inflammatory cytokine responses, inflammatory cell activation and enhanced generation of oxidative inflammatory mediators. This impacts the lung, increasing the severity of asthma and its exacerbations. This research will eva... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/29/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado
Conditions: Asthma, Obesity
Register for Updates
Investigating Dupilumab's Effect in Asthma by Genotype
NCT03694158
Recruiting
The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate of asthma exacerbations.
Gender:
All
Ages:
12 years and above
Trial Updated:
02/27/2024
Locations: Boston Children's Hospital, Boston, Massachusetts +6 locations
Conditions: Asthma
Register for Updates
Evaluate Pharmacokinetics and Safety of Slow Release DHEA
NCT05623059
Recruiting
This is a study to look at pharmacokinetic levels of different doses of slow release DHEA in subjects with severe asthma.
Gender:
All
Ages:
Between 18 years and 50 years
Trial Updated:
02/26/2024
Locations: Riley Hospital for Children, Indianapolis, Indiana +1 locations
Conditions: Asthma, Genotype
Register for Updates
NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)
NCT02327897
Recruiting
Background: - Asthma is a serious clinical and public health problem. Researchers want to collect data to better understand how bacteria and other things in the environment can affect people's asthma. Eligibility: - Nonsmoking adults age 18 - 60 who have moderate to severe asthma. Design: Participants will complete a medical history form before the first visit. Study visits will include collecting medical history, and conducting physical exam, lung and smoking tests. Participants will give... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/22/2024
Locations: NIEHS Clinical Research Unit (CRU), Research Triangle Park, North Carolina
Conditions: Asthma
Register for Updates
Individualizing Treatment for Asthma in Primary Care
NCT06272370
Recruiting
This is a patient level randomized trial for teenagers and adults with asthma who will be randomized to four arms - enhance usual care, rescue inhaled corticosteroids, azithromycin and both rescue inhaled corticosteroids and azithromycin. Participants in all arms will be offered access to an online asthma symptom monitoring system.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
02/20/2024
Locations: DARTNet Insitute, Aurora, Colorado
Conditions: Asthma, Bronchial Diseases, Respiratory Tract Infections, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Immune System Diseases
Register for Updates
The Dallas Asthma Brain and Cognition (ABC) Study
NCT03794856
Recruiting
Asthma is a chronic inflammatory airway disease that leads to episodic symptom exacerbations, which exerts a substantial burden on quality of life and can influence other health domains if not adequately controlled. Asthma prevalence rates have increased in the past decade, affecting 8.4% (25.7 million people) of the United States population. The economic costs of asthma have been estimated annually with $56 billion in the US alone. Despite progress in pharmacological treatment, overall asthma c... Read More
Gender:
All
Ages:
Between 40 years and 69 years
Trial Updated:
02/15/2024
Locations: Southern Methodist University, Dallas, Texas +1 locations
Conditions: Asthma
Register for Updates
Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics
NCT03953300
Recruiting
The purpose of the study is to evaluate effect of benralizumab on structural and lung function changes in severe eosinophilic asthmatics. Changes will be assessed over 48 week treatment period in patients with persistent symptoms despite standard therapy of inhaled corticosteroids (ICS) plus long acting B2-agonist (LABA) with or without additional controller medication. Patients who complete treatment will enter 4 weeks follow-up period.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
02/14/2024
Locations: Research Site, Los Angeles, California +40 locations
Conditions: Asthma
Register for Updates